

IN THE CLAIMS:

Claims 1 - 11 (Cancelled)

Claim 12 (currently amended): Biodegradable, monolithic antitumor composition with prolonged release of an antitumor agent ~~destined for the~~ administration into tissues, ~~characterized in that it comprises~~ comprising: at least one antitumor agent and a carrier, consisting of biodegradable oligoester, having the numeric mean relative molecular mass M_n from 650 to 7,500, the mass mean relative molecular mass M_w from 800 to 10,000 and the glass transition temperature T_g from -35 to 45°C [[.]], and which is prepared by polycondensation reaction of polyhydric alcohol containing at least 3 hydroxy groups with at least one aliphatic ahydroxy acid in the molar ratio of polyhydric alcohol to aliphatic a-hydroxy acid being from 0.5:99.5 to 12:88, wherein the essential molecule of biodegradable oligoester is a polyhydric alcohol, to the hydroxy groups of which chains created from several molecules of at least one aliphatic a-hydroxy acid are bound by ester bonds, and in that it is in the form of homogenous one-phase solution, micellar colloid system, one-phase or two-phase gel, suspension, paste or emulsion.

Claim 13 (currently amended): The composition according to Claim 12, further comprising at least one liquid biocompatible plasticizer, wherein the weight ~~ration~~ ratio of at least one biocompatible plasticizer to biodegradable oligoester is from 1:20 to [[9:20]] 9:10.

Claim 14 (previously presented): The composition according to Claim 13, wherein the liquid biocompatible plasticizer is soluble in the carrier and imperfectly soluble or

insoluble in water.

Claim 15 (previously presented): The composition according to Claim 12, further comprising at least one agent influencing the kinetics of the release of the antitumor agent.

Claim 16 (previously presented): The composition according to Claim 12, further comprising at least one stabilizer of the antitumor agent or carrier.

Claim 17 (currently amended): The preparation of the antitumor composition according to Claim 12, wherein an antitumor agent, a carrier, and optionally a liquid biocompatible plasticizer, an agent influencing the kinetics of the release of the antitumor agent, a stabilizer of the antitumor agent or a stabilizer of the carrier are ~~hated~~ heated to the temperature of 35 to 75° C[[.]] and mixed.